Brief: Liminal Enters Deal With Kedrion To Divest Unit

Liminal BioSciences

17/05/2021 14:17

May 17 (Reuters) - Liminal BioSciences Inc  LMNL.O :
    * PRESS RELEASE - LIMINAL BIOSCIENCES ENTERS INTO AGREEMENT
WITH
KEDRION TO DIVEST ITS PLASMA COLLECTION AND PLASMA-DERIVED
THERAPEUTICS BUSINESS
    * LIMINAL BIOSCIENCES INC - LIMINAL WOULD RECEIVE AN
AGGREGATE
PURCHASE PRICE OF USD 17 MILLION.
    * LIMINAL BIOSCIENCES - IF OPTION IS EXERCISED, KEDRION
WOULD
ASSUME MANUFACTURING AND COMMERCIALIZATION ACTIVITIES AND
OPERATING COSTS FOR RYPLAZIM
    * LIMINAL BIOSCIENCES INC - KEDRION CAN EXTEND OPTION FOR A
MAXIMUM OF THREE MONTHS IN EXCHANGE FOR A PAYMENT OF UP TO USD3M
PER MONTH

Source text for Eikon:  ID:nCNWNmDpGa 
Further company coverage:  LMNL.O 

 ((Reuters.Briefs@thomsonreuters.com;))